TriangleNCT01556438 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- GT60
- restrictive Agreement
- true
- limitations And Caveats
- description
- 300 mg tabalumab (LY2127399) group administered BTZ IV or SC data were combined per protocol in some instances as BTZ was a supplemental therapy for participants.
- point Of Contact
- organization
- Eli Lilly and Company
- phone
- 800-545-5979
- title
- Chief Medical Officer
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restriction Type
- GT60
- restrictive Agreement
- true
- limitations And Caveats
- description
- 300 mg tabalumab (LY2127399) group administered BTZ IV or SC data were combined per protocol in some instances as BTZ was a supplemental therapy for participants.
- point Of Contact
- organization
- Eli Lilly and Company
- phone
- 800-545-5979
- title
- Chief Medical Officer
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice